Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Entera Bio Ltd. develops oral peptide and protein replacement therapies targeting chronic conditions like osteoporosis and hypoparathyroidism. Utilizing its proprietary N-Tab platform, the company aims to replace injectable treatments with convenient daily tablets. Its pipeline includes first-in-class oral PTH and GLP programs, focusing on underserved markets and leveraging strategic collaborations to advance innovative, patient-friendly therapeutics.
This description was generated via AI from an annual report. Updated about 1 year ago.